September 28, 2020

The Niche

Knoepfler lab stem cell blog

Alta Charo

4 min read

Trying to make a CRISPR baby any time soon would be a really bad idea. How bad? Last December 3rd I penned a piece for STAT News arguing for a moratorium on the heritable use of CRISPR in humans. This potential future, radical application of “gene editing” is now often colloquially referred to as “CRISPR babies”. Read that piece for the reasons behind my thinking and the risks involved in leaving the door open to using CRISPR to make people. Of course, this was …Read More

3 min read

A National Academies panel on human genome editing chaired by Alta Charo and Richard Hynes released its report today. While it covered both somatic and germline (heritable) human genetic modification, the latter topic is far more contentious. You can see the National Academies summary of their report here. You can read the full report here. On germline genetic modification using technologies such as CRISPR, the authors of the report carefully discussed potential benefits and risks to the use of this technology. On my first brief …Read More

2 min read

A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, it seems like the first CRISPR IPO could get the lion’s share of investor money, but then there’s the patent thing hanging over all of this (see below) Patent …Read More